Synergistic effects of combined cisplatin and extract on triple negative breast cancer cells.

Objective: Triple negative breast cancer (TNBC) is the most invasive breast cancer subtype enriched with cancer stem cells. TNBCs do not express estrogen, progesterone, or human epidermal growth factor receptor 2 (HER2) receptors, making them difficult to be targeted by existing chemotherapy treatments. In this study, we attempted to identify the effects of combined cisplatin and treatment on MDA-MD-231 and MDA-MB-468 breast cancer cells, which represent TNBC subtypes.